Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '25100.009.615

Profile

Edit
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
URL https://www.apollomicsinc.com
Investor Relations URL https://ir.apollomicsinc.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 28, 2025 (est.)
Last Earnings Release Aug. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
URL https://www.apollomicsinc.com
Investor Relations URL https://ir.apollomicsinc.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Mar. 28, 2025 (est.)
Last Earnings Release Aug. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows